The Centers for Medicare & Medicaid Services (CMS) announced the payment adjustment, which could also include potential penalties for excess readmissions. The change is expected to increase total Medicare spending on inpatient hospital services by about $2.1 billion in the fiscal year beginning in October.
It's among changes proposed as part of the agency's annual Inpatient Prospective Payment System (IPPS), which governs reimbursement for inpatient care.
“Today’s payment rate announcement focuses on what matters most to help hospitals conduct their business and receive stable and consistent payment," CMS Administrator Seema Verma said in a statement.
The proposed changes also include creating a new hospital payment category for chimeric antigen receptor (CAR) T-cell therapy it says would provide a predictable rate to hospitals offering the treatment.
CAR-T therapy is the first gene therapy, and CMS began offering Medicare coverage for the treatment in some facilities in August 2019.
Currently, hospitals are paid the same for CAR-T as for bone marrow transplants and can seek additional payments through a temporary add-on for high-cost cases. That add-on expires this year, CMS said.
RELATED: CMS proposes updates to hospital wage index, payments for emerging therapies
In the rule, CMS also aims to make it easier for Medicare beneficiaries to access certain drugs targeting antibiotic-resistant infections and through a new add-on payment that can cover high-cost therapies.
In addition, CMS said it plans to collect certain data it mandated under its transparency rule, in particular hospitals' median payer-negotiated inpatient service charges in Medicare Advantage.